Should high mobility group box-1 protein (HMGB1) be measured in patients with severe sepsis and septic shock? If so, when, where, and how?

Critical Care Medicine

Volumn 33, Issue 3, 2005, Pages 682-683

  Eriksson, Mats ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Editorial; Endotoxin; High mobility group box 1 protein; Immunomodulation; Sepsis; Septic shock

Indexed keywords

HIGH MOBILITY GROUP 1 PROTEIN ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; EDITORIAL; GRAM NEGATIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; MEDICAL LITERATURE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; UNITED STATES;

ANTIBODIES; BIOLOGICAL MARKERS; CYTOKINES; HEALTH STATUS INDICATORS; HMGB1 PROTEIN; HUMANS; SEPSIS; SHOCK, SEPTIC; SWEDEN;

EID: 14944354286     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000155995.62327.93     Document Type: Editorial

References (13)

1. Kumar A, Bunnell E, Lynn M, et al: Experimental human endotoxemia is associated with depression of load-independent contractility indices: Prevention by the lipid a analogue E5531. Chest 2004; 126:860-867
2. Texereau J, Pene F, Chiche JD, et al: Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004; 32:8313-3319
3. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251
4. Yang H, Ochani M, Li J, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004; 101:296-301
5. Wang H, Liao H, Ochani M, et al: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10:1216-1221
6. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33:564-573
7. Parkkinen J, Raulo E, Merenmies J, et al: Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides: Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 1993; 268:19726-19738
8. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-871
9. Tracey KJ, Fong Y, Hesse DG, et al: Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
10. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351:929-933
11. Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999; 25:556-566
12. Manocha S, Feinstein D, Kumar A, et al: Novel therapies for sepsis: Antiendotoxin therapies. Expert Opin Invest Drugs 2002; 11:1795-1812
13. Gluck T, Opal SM: Advances in sepsis therapy. Drugs 2004; 64:837-859